miR-29b inhibits non-small cell lung cancer progression by targeting STRN4

被引:18
|
作者
Xie, Yuping [1 ]
Zhao, Fen [1 ]
Zhang, Ping [1 ]
Duan, Ping [1 ]
Shen, Yangmei [1 ,2 ]
机构
[1] Chengdu City First People's Hosp, Dept Oncology, Chengdu, Peoples R China
[2] w China Second Univ Hosp, Sichuan Univ, Dept Pathology, Chengdu, Peoples R China
关键词
miR-29b; STRN4; Non-small cell lung cancer; Progression; Overexpression; CALMODULIN-BINDING PROTEIN; STRIATIN; FAMILY; EXPRESSION; MICRORNAS; APOPTOSIS; MIGRATION; INVASION; STRIPAK; KINASE;
D O I
10.1007/s13577-019-00305-w
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Non-small cell lung cancer (NSCLC) is a malignant tumor with a high fatality, low overall cure, and survival rates worldwide. When only palliative therapy is available, the disease leads to malignant proliferation. Previous studies showed miR-29b serves as an NSCLC suppressor by inhibiting cells proliferation, migration, and invasion. However, the mechanism underlying NSCLC progression remains elusive. In this study, we identified Striatin 4 (STRN4), a target of miR-29b, which serves as a pro-oncogenic protein by promoting cells proliferation, migration, and invasion in NSCLC. Besides, the STRN4 was highly expressed in NSCLC and negatively regulated by miR-29b. Down-regulation of STRN4 inhibits NSCLC cells proliferation, migration, invasion, and promotes apoptosis in vitro, whereas overexpression-induced enhanced cell migration and invasion could be reverved by miR-29b. Notably, overexpression of miR-29b and down-regulation of STRN4 by shRNA suppressed cellular proliferation and delayed tumor progression in vivo. Together, these findings identify a miR-29b/STRN4 regulatory pathway in NSCLC progression, which may provide a new sight for the treatment of NSCLC.
引用
收藏
页码:220 / 231
页数:12
相关论文
共 50 条
  • [1] miR-29b inhibits non-small cell lung cancer progression by targeting STRN4
    Yuping Xie
    Fen Zhao
    Ping Zhang
    Ping Duan
    Yangmei Shen
    Human Cell, 2020, 33 : 220 - 231
  • [2] Long noncoding RNA TINCR promoted cell proliferation through sponging miR-29b in non-small cell lung cancer
    Liu, Guowei
    Yang, Huanjuan
    Xu, Caihua
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (07): : 6856 - 6862
  • [3] miR-29b inhibits the progression of esophageal squamous cell carcinoma by targeting MMP-2
    Qi, Y.
    Li, X.
    Zhao, S.
    NEOPLASMA, 2015, 62 (03) : 384 - 390
  • [4] miR-382 inhibits tumor progression by targeting SETD8 in non-small cell lung cancer
    Chen, Tianjun
    Ren, Hui
    Thakur, Asmitanand
    Yang, Tian
    Li, Yang
    Zhang, Shuo
    Wang, Ting
    Chen, Mingwei
    BIOMEDICINE & PHARMACOTHERAPY, 2017, 86 : 248 - 253
  • [5] miR-29b Mediates NF-κB Signaling in KRAS-Induced Non-Small Cell Lung Cancers
    Langsch, Stephanie
    Baumgartner, Ulrich
    Haemmig, Stefan
    Schlup, Cornelia
    Schafer, Stephan C.
    Berezowska, Sabina
    Rieger, Gregor
    Dorn, Patrick
    Tschan, Mario P.
    Vassella, Erik
    CANCER RESEARCH, 2016, 76 (14) : 4160 - 4169
  • [6] miR-140-3p inhibits progression of non-small cell lung cancer by targeting Janus kinase 1
    Chuan Hu
    Yong Zou
    Luan-Lian Jing
    Journal of Biosciences, 2020, 45
  • [7] miR-140-3p inhibits progression of non-small cell lung cancer by targeting Janus kinase 1
    Hu, Chuan
    Zou, Yong
    Jing, Luan-Lian
    JOURNAL OF BIOSCIENCES, 2020, 45 (01)
  • [8] MicroRNA-564 inhibits the progression of non-small cell lung cancer via targeting plexin A4
    Ding, Hui
    Li, Liangpeng
    Gu, Biao
    Ni, Yaojun
    Chen, Sheng
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (04)
  • [9] MiR-155 inhibits proliferation and invasion by directly targeting PDCD4 in non-small cell lung cancer
    Liu, Feng
    Song, Dalong
    Wu, Yanhu
    Liu, Xiang
    Zhu, Jinfu
    Tang, Yihu
    THORACIC CANCER, 2017, 8 (06) : 613 - 619
  • [10] MiRNA-621 inhibits the malignant progression of non-small cell lung cancer via targeting SIX4
    Zhang, M.
    Shi, H.
    Zhang, C.
    Zhang, S-Q
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (11) : 4807 - 4814